Pharmaceutical Industry

Drug Development Drug Pricing Drug Manufacturing Market Trends Market Competition Drug Manufacturers Market Dynamics Manufacturing Pricing Strategies Novo Nordisk

FDA Approves Orladeyo Oral Pellets to Prevent HAE Attacks in Children Ages 2 to Under 12

The decision relies on interim pediatric trial data showing tolerability with reduced attack rates.

Stories older than 24h

Lilly’s Triple‑Agonist Retatrutide Delivers Up to 28.7% Weight Loss in Phase 3, Easing Knee Pain

Prolynx Raises $70 Million to Advance Ultra-Long-Acting Obesity Drugs

Zealand Pharma Unveils ‘Metabolic Frontier 2030’ With Targets for Five Launches

FDA Class III Recall Targets 11,136 Bottles of Ziac Over Trace Ezetimibe Contamination

Yahoo Finance Highlights Merck and Bristol Myers as Value Plays Outside the GLP-1 Surge

Roche’s Giredestrant Cuts Early Breast Cancer Recurrence 30% in Phase III Trial

UK Cuts NHS Rebate on New Branded Drugs to 14.5% for 2026 Under US Trade Framework

FDA Fast-Tracks Augmentin XR in First Approval Under National Priority Voucher Pilot

Terns’ TERN-701 Shows Strong CML Responses in CARDINAL, Setting 320 mg and 500 mg Phase 2 Doses

FDA Approves Breyanzi for Marginal Zone Lymphoma After Two or More Therapies

FDA Grants Conditional Approval to Exzolt Cattle-CA1 for Screwworm and Cattle Fever Tick

Okava Launches First GLP-1 Implant Trial for Overweight Cats

Bristol Myers Delays ADEPT-2 Alzheimer’s Psychosis Readout to 2026 After Site Irregularities

Pharvaris’ Oral HAE Drug Deucrictibant Delivers Rapid Relief in Pivotal Phase 3

Capricor’s HOPE-3 Trial Reports Cardiac and Muscle Gains in Duchenne Muscular Dystrophy

U.S. and U.K. Seal Three-Year Zero‑Tariff Pharma Deal Tied to Higher NHS Drug Prices

FDA Issues Draft Guidance Easing Primate Tests for Some Antibody Drugs

Lilly Cuts Zepbound Cash Prices on LillyDirect as GLP‑1 Price Competition Deepens

Regeneron, Tessera Strike $150 Million Gene-Editing Pact for Alpha‑1 Antitrypsin Deficiency